[Proton therapy in France in 2019].

État des lieux de la protonthérapie en France en 2019.

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 16 06 2019
accepted: 04 07 2019
pubmed: 4 9 2019
medline: 8 10 2019
entrez: 4 9 2019
Statut: ppublish

Résumé

Among over 100 proton therapy centres worldwide in operation or under construction, French proton therapy is coming to full maturity with the recent opening of the Nice (1991, upgrade in 2016) and Caen (2018) facilities next to the Orsay (1991, upgrade in 2010) centre. Proton therapy is a national priority for children and young adults in all three centres. The patient-related activity of the three French centres is coordinated via the Protonshare portal to optimise referral by type of indication and available expertise in coordination with the French society of radiation oncology SFRO and French radiotherapy centres. The centres are recognised by the French Health Care excellence initiative, promoted by the ministry of Foreign Affairs. The three centres collaborate structurally in terms of clinical research and are engaged at the international level in the participation to European databases and research initiatives. Concerted actions are now also promoted in preclinical research via the Radiotransnet network. Ongoing French developments in proton therapy are well presented in international hadron therapy meetings, including European Proton Therapy Network and Particle Therapy Cooperative Oncology Group. Proton therapy teaching in France is offered at several levels and is open to colleagues from all radiation oncology centres, so that they are fully informed, involved and trained to facility recognition of possible indications and thereby to contribute to appropriate patient referral. This close collaboration between all actors in French radiation oncology facilitates the work to demonstrate the required level of medical and scientific evidence for current and emerging indications for particle therapy. Based on that, the future might entail a possible creation of more proton therapy facilities in France.

Identifiants

pubmed: 31477441
pii: S1278-3218(19)30303-8
doi: 10.1016/j.canrad.2019.07.129
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

617-624

Informations de copyright

Copyright © 2019. Published by Elsevier Masson SAS.

Auteurs

R Dendale (R)

Department of radiation oncology, institut Curie, centre de protonthérapie d'Orsay, bâtiment 101, campus universitaire d'Orsay, 91898 Orsay cedex, France.

J Thariat (J)

Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France; Normandie université, 14000 Caen, France; Laboratoire de physique corpusculaire IN2P3/UMR6534, Ensicaen, 14000 Caen, France.

J Doyen (J)

Department of Radiation Oncology, centre Antoine-Lacassagne, 33, avenue Valombrose, 06000 Nice, France; Université Nice-Sophia-Antipolis, 06000 Nice, France.

J Balosso (J)

Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France.

D Stefan (D)

Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France.

S Bolle (S)

Department of Radiation Oncology, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.

L Feuvret (L)

Department of Radiation Oncology, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'hôpital, 75651 Paris cedex 13, France.

P Poortmans (P)

Department of radiation oncology, institut Curie, centre de protonthérapie d'Orsay, bâtiment 101, campus universitaire d'Orsay, 91898 Orsay cedex, France.

J-M Hannoun-Lévi (JM)

Department of Radiation Oncology, centre Antoine-Lacassagne, 33, avenue Valombrose, 06000 Nice, France; Université Nice-Sophia-Antipolis, 06000 Nice, France.

P-Y Bondiau (PY)

Department of Radiation Oncology, centre Antoine-Lacassagne, 33, avenue Valombrose, 06000 Nice, France.

M Micaud (M)

Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France.

C Alapetite (C)

Department of radiation oncology, institut Curie, centre de protonthérapie d'Orsay, bâtiment 101, campus universitaire d'Orsay, 91898 Orsay cedex, France.

V Calugaru (V)

Department of radiation oncology, institut Curie, centre de protonthérapie d'Orsay, bâtiment 101, campus universitaire d'Orsay, 91898 Orsay cedex, France.

J-L Habrand (JL)

Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France; Normandie université, 14000 Caen, France.

M-A Mahé (MA)

Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France; Normandie université, 14000 Caen, France. Electronic address: ma.mahe@baclesse.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH